Acellular dermal matrices, also known as acellular dermal matrix or cadaveric dermis, are tissue allografts used in reconstructive procedures. They are obtained from donated human skin tissues that have undergone a tissue processing methodology to remove the epidermis and all cellular components, leaving behind a collagen-rich extracellular matrix scaffold. Such dermal matrices offer a suitable replacement when a person’s own tissue is inadequate or unavailable. They are often used in breast reconstruction and soft tissue repair surgeries to reinforce, support, and cover implants or areas of weakness or absence. With a growing emphasis on breast reconstruction surgeries post-cancer treatment and a rise in accidents and sports injuries necessitating soft tissue repair and replacement, the demand for acellular dermal matrices is surging in the U.S. healthcare industry.
The global U.S. Acellular Dermal Matrices Market is estimated to be valued at US$ 2783.32 Mn in 2023 and is expected to exhibit a CAGR of 5.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the U.S. acellular dermal matrices market is the development of regenerative therapies. Companies are investing heavily in research to develop acellular dermal matrices with bioactive components and growth factors that can stimulate collagen production and regenerate native tissue in situ. These next-generation dermal matrices aim to provide natural-like skin repair while avoiding complications associated with synthetic meshes or autografting. They eliminate the need to harvest additional tissue from patients. The ability to regenerate tissues endogenously could significantly expand the scope of procedures using acellular dermal matrices and further accelerate revenue growth in the coming years.
Threat of new entrants: Low, as establishing manufacturing plants and obtaining regulatory approvals from the FDA require large investments of capital and time.
Bargaining power of buyers: Moderate, as the presence of various established manufacturers limits the control large buyers can exercise over prices.
Bargaining power of suppliers: Low, as key raw materials are commodities and manufacturers can easily switch between suppliers.
Threat of new substitutes: Low, as there are currently no clinically viable substitutes for acellular dermal matrices.
Competitive rivalry: High, as the market is consolidated with the presence of few large players focusing on new product development and expansion into new regions.
The Global U.S. Acellular Dermal Matrices Market Demand is expected to witness high growth. The global U.S. Acellular Dermal Matrices Market is estimated to be valued at US$ 2783.32 Mn in 2023 and is expected to exhibit a CAGR of 5.5% over the forecast period 2023 to 2030.
The North America region currently dominates the U.S. acellular dermal matrices market due to high awareness among patients and physicians. However, the Asia Pacific region is expected to grow at the fastest pace during the forecast period owing to increasing medical tourism and developing healthcare infrastructure.
Key players related content comprises Key players operating in the U.S. Acellular Dermal Matrices Market are Biomet, Inc., Wright Medical Technology, Inc., Smith & Nephew Plc, and Stryker. Biomet has a strong footprint in the United States and focuses on developing cost-effective acellular dermal matrices to strengthen its market position. Wright Medical primarily focuses on shoulder and ankle reconstruction applications and maintains a wide distribution network across the US.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it